Related Experiment Video
Updated: Sep 19, 2025

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Naproxen and prednisolone reduced intestinal alteration and permeability and bacterial translocation in rat
Sophie Hecquet1,2, Perle Totoson1, Hélène Martin1
1UMR 1098 INSERM EFS RIGHT - équipe TAI-IT, Université de Bourgogne Franche-Comté, UFR Sciences de Santé, 19 Rue Ambroise Paré, Bâtiment S, 25030, Besançon, France.
Background:
In patients with spondyloarthritis, intestinal permeability (IP) and bacterial translocation (BT) has been described as increased. Anti-inflammatory medications are known to induce deleterious intestinal changes in the general population, their effects in case of arthritis have been poorly studied.
Objectives:
To assess the effect of NSAIDs and glucocorticoids on IP, BT and intestinal integrity in rats with adjuvant-induced arthritis (AIA).
Methods:
Arthritis was induced in 6-week-old male Lewis rats by injection at the base of the tail of Mycobacterium butyricum. At first signs of arthritis, rats were treated daily with naproxen, diclofenac, celecoxib, prednisolone or vehicle (saline). After 21 days of treatment, intestinal damage was determined by measure of levels of intestinal Fatty Acid Binding Protein (iFABP, ELISA), IP by measure of levels of zonulin and BT by measure of levels of soluble CD14 (sCD14, ELISA) and LPS (by liquid chromatography coupled mass spectrometry). Articular inflammation was assessed by the determination of an arthritis and radiographic score.
Results:
All treatments reduced and radiographic score in AIA rats (p < 0.05) compared to vehicle. In comparison with AIA, treatment with naproxen significantly reduced circulating zonulin, iFABP, LPS and sCD14 levels. Celecoxib increased zonulin but had no effect on iFABP levels. Diclofenac increased LPS levels but did not change sCD14 or iFABP levels. Prednisolone only reduced iFABP and sCD14 levels.
Conclusions:
Our study is the first to demonstrate the positive effects of naproxen, a non-selective COX inhibitor and prednisolone on the intestinal barrier in a murine model of reactive arthritis-type spondyloarthritis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

